SML2156

Erlotinib hydrochloride

Name: Erlotinib hydrochloride
Brand: SIGMA

≥98% (HPLC), EGFR kinase inhibitor, powder

Sinónimos:

774 hydrochloride, CP-358, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, OSI-744 hydrochloride

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₂₂H₂₃N₃O₄ · HCl

Número CAS:

183319-69-9

Peso molecular:

429.90

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD07781272

Nombre del producto

Erlotinib hydrochloride, ≥98% (HPLC)

SMILES string

Cl.N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC

InChI

1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

InChI key

GTTBEUCJPZQMDZ-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

Categorías relacionadas

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Application

Erlotinib hydrochloride has been used to activate mitochondrial fragmentation in a human PANC-1 pancreatic cancer cell line.

Biochem/physiol Actions

EGFR kinase inhibitor; Antineoplastic

Erlotinib hydrochloride is an inhibitor of the receptor tyrosine kinase EGFR (epidermal growth factor receptor). It is used clinically for the treatment of non-small cell lung cancer (NSCLC) and in combination for metastatic pancreatic cancer.

General description

Erlotinib hydrochloride is an antineoplastic drug. It regulates mechanistic target of rapamycin (mTOR) inhibition, epidermal growth factor receptor down-regulation and epidermal interstitial transformation (EMT) suppression.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

0000507102

0000472016

0000455118

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

J D Moyer et al.

Cancer research, 57(21), 4838-4848 (1997-11-14)

The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype. CP-358,774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR

Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death.

Rabea Oberthür et al.

Cancer letters, 407, 93-105 (2017-08-22)

Overexpression and activation of receptor tyrosine kinases (RTKs), such as the insulin-like growth factor 1 receptor (IGF1R) and the epidermal growth factor receptor (EGFR), are frequent phenomena in colorectal cancer (CRC). Here, we evaluated the effect and the cellular mechanisms

Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy.

Kandasamy Saravanakumar et al.

Carbohydrate polymers, 245, 116407-116407 (2020-07-29)

The present work was developed the pH dependent-aptamer AS1411 (APT) decorated and erlotinib (En) loaded chitosan nanoparticles (CSNPs) for promising non-small-cell lung carcinoma (NSCLC) treatment. The characterization studies revealed that formulated APT-En-CSNPs were spherical in shape with size of 165.95

Analytical Methods for Therapeutic Drug Monitoring and Toxicology (2011)

Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activating the mROS-HtrA2/Omi pathways

Wan J, et al.

Cancer Cell International, 18(1), 165-165 (2018)

Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico